2002
DOI: 10.1016/s0924-977x(02)80707-6
|View full text |Cite
|
Sign up to set email alerts
|

Citalopram for compulsive shopping disorder: A double-blind study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
46
1
7

Year Published

2004
2004
2014
2014

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 35 publications
(56 citation statements)
references
References 0 publications
2
46
1
7
Order By: Relevance
“…Double-blind, placebo-controlled trials should be conducted to test the relative effectiveness of various medications, particularly serotonergically active drugs that have been shown to be effective in other disorders of impulse control. [18][19][20] Drug names: buspirone (BuSpar and others), escitalopram (Lexapro), fluoxetine (Prozac and others), lithium (Lithobid, Eskalith, and others), naltrexone (Revia and others), sertraline (Zoloft), topiramate (Topamax), trazodone (Desyrel and others), valproic acid (Depakene and others).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Double-blind, placebo-controlled trials should be conducted to test the relative effectiveness of various medications, particularly serotonergically active drugs that have been shown to be effective in other disorders of impulse control. [18][19][20] Drug names: buspirone (BuSpar and others), escitalopram (Lexapro), fluoxetine (Prozac and others), lithium (Lithobid, Eskalith, and others), naltrexone (Revia and others), sertraline (Zoloft), topiramate (Topamax), trazodone (Desyrel and others), valproic acid (Depakene and others).…”
Section: Resultsmentioning
confidence: 99%
“…9,[14][15][16][17] Given the success in double-blind placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) in the treatment of other impulse control disorders, [18][19][20] it is plausible that kleptomania may be similarly responsive. We are currently conducting the first double-blind placebo-controlled trial to test this hypothesis, using the SSRI escitalopram.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the high prevalence and the detrimental impact for both, the individual and the society, studies investigating single facets of pathological buying such as neuropsychological or neurobiological correlates are scarce so far. The serotonergic, dopaminergic and opioide systems may be involved in the aetiology and pathogenesis of pathological buying (Grant, 2003;Koran, Aboujaoude, Solvason, Gamel & Smith, 2007;Koran, Chuong, Bullock & Smith, 2003). On a neural level, one assumes dysfunctions in cognitive (dorsolateral prefrontal cortex, nucleus caudatus) and affective brain circuits (ventromedial prefrontal/orbitofrontal cortex, nucleus accumbens, anterior cingulate cortex, basolateral amygdala) (review in Black, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…Although a role has been suggested for opiate, serotonergic, and dopaminergic systems dysfunctions in this condition, the precise alterations in these neurotransmitters are still unclear [6]. For instance, the evidence supporting the utility of serotonin reuptake inhibitors in compulsive buying is mixed, i.e., while citalopram has shown some benefit [13], escitalopram [14] and fluvoxamine did not [15,16]. One additional concern is that the number of different buying behaviors required to qualify compulsive buying as potentially addictive, is unclear [17].…”
Section: Compulsive Buyingmentioning
confidence: 99%